Paclitaxel Treatment Options in Canada

A collection of 342 research studies where Paclitaxel is the interventional treatment. These studies are located in the Canada . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Home

Canada

All Treatments

Paclitaxel

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00023673

Completed

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them with specialized radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the effectiveness of radiation therapy combined with paclitaxel and carboplatin in treating patients who have stage III non... Read More

Gender:

ALL

Ages:

All

Trial Updated:

11/27/2017

Locations: Mobile Infirmary Medical Center, Mobile, Alabama +40 locations

Mobile Infirmary Medical Center, Mobile, Alabama

Arizona Oncology Services Foundation, Phoenix, Arizona

Providence Saint Joseph Medical Center - Burbank, Burbank, California

Providence Holy Cross Cancer Center, Mission Hills, California

University of California Davis Cancer Center, Sacramento, California

Bay Medical, Panama City, Florida

Northeast Georgia Medical Center, Gainesville, Georgia

Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois

Alexian Brothers Radiation Oncology, Elk Grove Village, Illinois

Good Samaritan Regional Health Center, Mount Vernon, Illinois

Oncology Center at Saint Margaret Mercy Healthcare Center, Hammond, Indiana

Cancer Center at Ball Memorial Hospital, Muncie, Indiana

Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi

Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital, Cape Girardeau, Missouri

Cancer Institute of Cape Girardeau, LLC, Cape Girardeau, Missouri

Saint Francis Medical Center, Cape Girardeau, Missouri

CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri

David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri

CCOP - Cancer Research for the Ozarks, Springfield, Missouri

Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri

Ocean Medical Center at Meridian Health, Brick, New Jersey

J. Phillip Citta Regional Cancer Center at Community Medical Center, Toms River, New Jersey

Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare, Vineland, New Jersey

CCOP - Hematology-Oncology Associates of Central New York, East Syracuse, New York

High Point Regional Hospital, High Point, North Carolina

Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio

Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Cancer Treatment Center, Wooster, Ohio

Three Rivers Community Hospital, Grants Pass, Oregon

Dubs Cancer Center at Rogue Valley Medical Center, Medford, Oregon

Providence Cancer Center at PMCC, Medford, Oregon

Albert Einstein Cancer Center, Philadelphia, Pennsylvania

Rapid City Regional Hospital, Rapid City, South Dakota

University of Texas Medical Branch, Galveston, Texas

Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas

Schiffler Cancer Center at Wheeling Hospital, Wheeling, West Virginia

Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center, La Crosse, Wisconsin

Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin

Veterans Affairs Medical Center - Milwaukee, Milwaukee, Wisconsin

Tom Baker Cancer Centre - Calgary, Calgary, Alberta

Conditions: Lung Cancer

Learn More ›

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

NCT01862081

Completed

This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0032 administered in combination with either docetaxel or with paclitaxel. Patients treated with the GDC-0032 and docetaxel have HER2-negative locally recurrent or metastatic breast cancer or non-small cell lung cancer (NSCLC). Patients treated with the GDC-0032 and paclitaxel combination have human epidermal growth factor receptor 2 (HER2)-negative locally recu... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/27/2017

Locations: Florida Cancer Specialists - Tampa (Dr. MLK Blvd), Tampa, Florida +13 locations

Conditions: Breast Cancer, Non-small Lung Cancer

Learn More ›

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

NCT01192165

Completed

The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, erlotinib, pemetrexed, pemetrexed + carboplatin, pemetrexed + cisplatin, or nab-paclitaxel). The doses identified in this study may be used in future trials to test whether the combination treatment i... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/08/2017

Locations: GSK Investigational Site, Scottsdale, Arizona +19 locations

Conditions: Cancer

Learn More ›

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

NCT01015118

Completed

The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

11/03/2017

Locations: 1199.15.10113 Boehringer Ingelheim Investigational Site, Tucson, Arizona +280 locations

1199.15.10113 Boehringer Ingelheim Investigational Site, Tucson, Arizona

1199.15.10030 Boehringer Ingelheim Investigational Site, Long Beach, California

1199.15.10001 Boehringer Ingelheim Investigational Site, Santa Rosa, California

1199.15.10005 Boehringer Ingelheim Investigational Site, Englewood, Colorado

1199.15.10028 Boehringer Ingelheim Investigational Site, New Haven, Connecticut

1199.15.10014 Boehringer Ingelheim Investigational Site, Orlando, Florida

1199.15.10010 Boehringer Ingelheim Investigational Site, Augusta, Georgia

1199.15.10004 Boehringer Ingelheim Investigational Site, Savannah, Georgia

1199.15.10011 Boehringer Ingelheim Investigational Site, Louisville, Kentucky

1199.15.10003 Boehringer Ingelheim Investigational Site, Marrero, Louisiana

1199.15.10017 Boehringer Ingelheim Investigational Site, Detroit, Michigan

1199.15.10103 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota

1199.15.10002 Boehringer Ingelheim Investigational Site, New York, New York

1199.15.10012 Boehringer Ingelheim Investigational Site, Charlotte, North Carolina

1199.15.10020 Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina

1199.15.10019 Boehringer Ingelheim Investigational Site, Bismarck, North Dakota

1199.15.10024 Boehringer Ingelheim Investigational Site, Canton, Ohio

1199.15.10025 Boehringer Ingelheim Investigational Site, Cleveland, Ohio

1199.15.10029 Boehringer Ingelheim Investigational Site, Cleveland, Ohio

1199.15.10021 Boehringer Ingelheim Investigational Site, Portland, Oregon

1199.15.10013 Boehringer Ingelheim Investigational Site, Abington, Pennsylvania

1199.15.10016 Boehringer Ingelheim Investigational Site, Allentown, Pennsylvania

1199.15.10008 Boehringer Ingelheim Investigational Site, Providence, Rhode Island

1199.15.10102 Boehringer Ingelheim Investigational Site, Greenville, South Carolina

1199.15.10006 Boehringer Ingelheim Investigational Site, Chattanooga, Tennessee

1199.15.10104 Boehringer Ingelheim Investigational Site, Austin, Texas

1199.15.10100 Boehringer Ingelheim Investigational Site, Bedford, Texas

1199.15.10107 Boehringer Ingelheim Investigational Site, Dallas, Texas

1199.15.10108 Boehringer Ingelheim Investigational Site, Dallas, Texas

1199.15.10110 Boehringer Ingelheim Investigational Site, Fort Worth, Texas

1199.15.10007 Boehringer Ingelheim Investigational Site, Houston, Texas

1199.15.10105 Boehringer Ingelheim Investigational Site, Spokane, Washington

1199.15.10112 Boehringer Ingelheim Investigational Site, Vancouver, Washington

1199.15.61006 Boehringer Ingelheim Investigational Site, Camperdown, New South Wales

1199.15.61001 Boehringer Ingelheim Investigational Site, Waratah, New South Wales

1199.15.61004 Boehringer Ingelheim Investigational Site, Herston, Queensland

1199.15.61003 Boehringer Ingelheim Investigational Site, Southe Brisbane, Queensland

1199.15.61005 Boehringer Ingelheim Investigational Site, North Terrace, South Australia

1199.15.61007 Boehringer Ingelheim Investigational Site, Parkville, Victoria

1199.15.61002 Boehringer Ingelheim Investigational Site, Nedlands, Western Australia

1199.15.43003 Boehringer Ingelheim Investigational Site, Graz, Not set

1199.15.43001 Boehringer Ingelheim Investigational Site, Innsbruck, Not set

1199.15.43011 Boehringer Ingelheim Investigational Site, Krems, Not set

1199.15.43007 Boehringer Ingelheim Investigational Site, Kufstein, Not set

1199.15.43005 Boehringer Ingelheim Investigational Site, Linz, Not set

1199.15.43010 Boehringer Ingelheim Investigational Site, Salzburg, Not set

1199.15.43013 Boehringer Ingelheim Investigational Site, Wels, Not set

1199.15.43002 Boehringer Ingelheim Investigational Site, Wien, Not set

1199.15.43012 Boehringer Ingelheim Investigational Site, Wien, Not set

1199.15.32010 Boehringer Ingelheim Investigational Site, Edegem, Not set

1199.15.32012 Boehringer Ingelheim Investigational Site, Hasselt, Not set

1199.15.32003 Boehringer Ingelheim Investigational Site, La Louvière, Not set

1199.15.32001 Boehringer Ingelheim Investigational Site, Leuven, Not set

1199.15.32007 Boehringer Ingelheim Investigational Site, Liège, Not set

1199.15.32008 Boehringer Ingelheim Investigational Site, Sint-Niklaas, Not set

1199.15.11005 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia

1199.15.11004 Boehringer Ingelheim Investigational Site, Hamilton, Ontario

1199.15.11008 Boehringer Ingelheim Investigational Site, London, Ontario

1199.15.11009 Boehringer Ingelheim Investigational Site, Toronto, Ontario

1199.15.11003 Boehringer Ingelheim Investigational Site, Montreal, Quebec

1199.15.11006 Boehringer Ingelheim Investigational Site, Montreal, Quebec

1199.15.11001 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec

1199.15.42002 Boehringer Ingelheim Investigational Site, Brno, Not set

1199.15.42003 Boehringer Ingelheim Investigational Site, Olomouc, Not set

1199.15.42001 Boehringer Ingelheim Investigational Site, Prague, Not set

1199.15.45004 Boehringer Ingelheim Investigational Site, Aalborg, Not set

1199.15.45002 Boehringer Ingelheim Investigational Site, Herlev, Not set

1199.15.45005 Boehringer Ingelheim Investigational Site, Herning, Not set

1199.15.45001 Boehringer Ingelheim Investigational Site, Købenahvn Ø, Not set

1199.15.45003 Boehringer Ingelheim Investigational Site, Odense C, Not set

1199.15.35801 Boehringer Ingelheim Investigational Site, Helsinki, Not set

1199.15.35804 Boehringer Ingelheim Investigational Site, Jyväskylä, Not set

1199.15.35805 Boehringer Ingelheim Investigational Site, Kuopio, Not set

1199.15.35803 Boehringer Ingelheim Investigational Site, Oulu, Not set

1199.15.35802 Boehringer Ingelheim Investigational Site, Tampere, Not set

1199.15.33047 Boehringer Ingelheim Investigational Site, Aix-en-Provence, Not set

1199.15.33035 Boehringer Ingelheim Investigational Site, Avignon cedex 02, Not set

1199.15.33055 Boehringer Ingelheim Investigational Site, Besançon, Not set

1199.15.33003 Boehringer Ingelheim Investigational Site, Bordeaux cedex, Not set

1199.15.33004 Boehringer Ingelheim Investigational Site, Bordeaux, Not set

1199.15.33006 Boehringer Ingelheim Investigational Site, Caen cedex 5, Not set

1199.15.33025 Boehringer Ingelheim Investigational Site, Clermont-Ferrand cedex, Not set

1199.15.33048 Boehringer Ingelheim Investigational Site, Dechy, Not set

1199.15.33042 Boehringer Ingelheim Investigational Site, Fréjus, Not set

1199.15.33037 Boehringer Ingelheim Investigational Site, La Roche-Sur-Yon cedex 09, Not set

1199.15.33008 Boehringer Ingelheim Investigational Site, Le Mans, Not set

1199.15.33009 Boehringer Ingelheim Investigational Site, Lille cedex, Not set

1199.15.33020 Boehringer Ingelheim Investigational Site, Lyon, Not set

1199.15.33011 Boehringer Ingelheim Investigational Site, Marseille cedex 09, Not set

1199.15.33021 Boehringer Ingelheim Investigational Site, Monaco Cedex, Not set

1199.15.33012 Boehringer Ingelheim Investigational Site, Mont-de-Marsan cedex, Not set

1199.15.33052 Boehringer Ingelheim Investigational Site, Montpellier cedex 5, Not set

1199.15.33053 Boehringer Ingelheim Investigational Site, Mougins, Not set

1199.15.33038 Boehringer Ingelheim Investigational Site, Nancy, Not set

1199.15.33013 Boehringer Ingelheim Investigational Site, Nantes cedex 02, Not set

1199.15.33015 Boehringer Ingelheim Investigational Site, Orléans cedex 02, Not set

1199.15.33027 Boehringer Ingelheim Investigational Site, Paris cedex 20, Not set

1199.15.33001 Boehringer Ingelheim Investigational Site, Paris, Not set

1199.15.33051 Boehringer Ingelheim Investigational Site, PERIGUEUX Cedex, Not set

1199.15.33030 Boehringer Ingelheim Investigational Site, Plerin SUR MER, Not set

1199.15.33045 Boehringer Ingelheim Investigational Site, Saint Cloud, Not set

1199.15.33033 Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, Not set

1199.15.33018 Boehringer Ingelheim Investigational Site, Strasbourg cedex, Not set

1199.15.33039 Boehringer Ingelheim Investigational Site, Thonon-Les-Bains, Not set

1199.15.33031 Boehringer Ingelheim Investigational Site, Vandoeuvre les Nancy cedex, Not set

1199.15.33050 Boehringer Ingelheim Investigational Site, Villejuif Cedex, Not set

1199.15.49040 Boehringer Ingelheim Investigational Site, Aachen, Not set

1199.15.49070 Boehringer Ingelheim Investigational Site, Aalen, Not set

1199.15.49086 Boehringer Ingelheim Investigational Site, Aschaffenburg, Not set

1199.15.49002 Boehringer Ingelheim Investigational Site, Berlin, Not set

1199.15.49039 Boehringer Ingelheim Investigational Site, Berlin, Not set

1199.15.49041 Boehringer Ingelheim Investigational Site, Berlin, Not set

1199.15.49004 Boehringer Ingelheim Investigational Site, Bonn, Not set

1199.15.49042 Boehringer Ingelheim Investigational Site, Bonn, Not set

1199.15.49071 Boehringer Ingelheim Investigational Site, Bottrop, Not set

1199.15.49081 Boehringer Ingelheim Investigational Site, Böblingen, Not set

1199.15.49043 Boehringer Ingelheim Investigational Site, Chemnitz, Not set

1199.15.49005 Boehringer Ingelheim Investigational Site, Dessau, Not set

1199.15.49006 Boehringer Ingelheim Investigational Site, Detmold, Not set

1199.15.49007 Boehringer Ingelheim Investigational Site, Dresden, Not set

1199.15.49067 Boehringer Ingelheim Investigational Site, Dresden, Not set

1199.15.49008 Boehringer Ingelheim Investigational Site, Düsseldorf, Not set

1199.15.49009 Boehringer Ingelheim Investigational Site, Ebersberg, Not set

1199.15.49010 Boehringer Ingelheim Investigational Site, Essen, Not set

1199.15.49066 Boehringer Ingelheim Investigational Site, Essen, Not set

1199.15.49089 Boehringer Ingelheim Investigational Site, Essen, Not set

1199.15.49045 Boehringer Ingelheim Investigational Site, Frankfurt, Not set

1199.15.49011 Boehringer Ingelheim Investigational Site, Freiburg, Not set

1199.15.49068 Boehringer Ingelheim Investigational Site, Freiburg, Not set

1199.15.49083 Boehringer Ingelheim Investigational Site, Freudenstadt, Not set

1199.15.49046 Boehringer Ingelheim Investigational Site, Fulda, Not set

1199.15.49012 Boehringer Ingelheim Investigational Site, Fürstenfeldbruck, Not set

1199.15.49064 Boehringer Ingelheim Investigational Site, Greifswald, Not set

1199.15.49076 Boehringer Ingelheim Investigational Site, Gütersloh, Not set

1199.15.49014 Boehringer Ingelheim Investigational Site, Halle/S., Not set

1199.15.49015 Boehringer Ingelheim Investigational Site, Hamburg, Not set

1199.15.49084 Boehringer Ingelheim Investigational Site, Hamburg, Not set

1199.15.49073 Boehringer Ingelheim Investigational Site, Hanau, Not set

1199.15.49095 Boehringer Ingelheim Investigational Site, Heidelberg, Not set

1199.15.49080 Boehringer Ingelheim Investigational Site, Henstedt-Ulzburg, Not set

1199.15.49047 Boehringer Ingelheim Investigational Site, Hildesheim, Not set

1199.15.49016 Boehringer Ingelheim Investigational Site, Karlsruhe, Not set

1199.15.49017 Boehringer Ingelheim Investigational Site, Kiel, Not set

1199.15.49062 Boehringer Ingelheim Investigational Site, Krefeld, Not set

1199.15.49018 Boehringer Ingelheim Investigational Site, Landshut, Not set

1199.15.49087 Boehringer Ingelheim Investigational Site, Ludwigsburg, Not set

1199.15.49019 Boehringer Ingelheim Investigational Site, Lübeck, Not set

1199.15.49020 Boehringer Ingelheim Investigational Site, Magdeburg, Not set

1199.15.49021 Boehringer Ingelheim Investigational Site, Mainz, Not set

1199.15.49022 Boehringer Ingelheim Investigational Site, Mainz, Not set

1199.15.49023 Boehringer Ingelheim Investigational Site, Mannheim, Not set

1199.15.49024 Boehringer Ingelheim Investigational Site, Marburg, Not set

1199.15.49025 Boehringer Ingelheim Investigational Site, München, Not set

1199.15.49026 Boehringer Ingelheim Investigational Site, München, Not set

1199.15.49027 Boehringer Ingelheim Investigational Site, München, Not set

1199.15.49048 Boehringer Ingelheim Investigational Site, München, Not set

1199.15.49065 Boehringer Ingelheim Investigational Site, Neumarkt i.d.Opf., Not set

1199.15.49029 Boehringer Ingelheim Investigational Site, Offenbach, Not set

1199.15.49082 Boehringer Ingelheim Investigational Site, Paderborn, Not set

1199.15.49030 Boehringer Ingelheim Investigational Site, Radebeul, Not set

1199.15.49061 Boehringer Ingelheim Investigational Site, Ravensburg, Not set

1199.15.49050 Boehringer Ingelheim Investigational Site, Regensburg, Not set

1199.15.49051 Boehringer Ingelheim Investigational Site, Rosenheim, Not set

1199.15.49052 Boehringer Ingelheim Investigational Site, Rostock, Not set

1199.15.49054 Boehringer Ingelheim Investigational Site, Saalfeld, Not set

1199.15.49031 Boehringer Ingelheim Investigational Site, Salzgitter, Not set

1199.15.49055 Boehringer Ingelheim Investigational Site, Solingen, Not set

1199.15.49092 Boehringer Ingelheim Investigational Site, Stadthagen, Not set

1199.15.49063 Boehringer Ingelheim Investigational Site, Stendal, Not set

1199.15.49093 Boehringer Ingelheim Investigational Site, Stralsund, Not set

1199.15.49033 Boehringer Ingelheim Investigational Site, Stuttgart, Not set

1199.15.49056 Boehringer Ingelheim Investigational Site, Stuttgart, Not set

1199.15.49090 Boehringer Ingelheim Investigational Site, Stuttgart, Not set

1199.15.49079 Boehringer Ingelheim Investigational Site, Suhl, Not set

1199.15.49034 Boehringer Ingelheim Investigational Site, Traunstein, Not set

1199.15.49057 Boehringer Ingelheim Investigational Site, Trier, Not set

1199.15.49035 Boehringer Ingelheim Investigational Site, Tübingen, Not set

1199.15.49058 Boehringer Ingelheim Investigational Site, Ulm, Not set

1199.15.49085 Boehringer Ingelheim Investigational Site, Viersen, Not set

1199.15.49001 Boehringer Ingelheim Investigational Site, Wiesbaden, Not set

1199.15.49036 Boehringer Ingelheim Investigational Site, Wiesbaden, Not set

1199.15.49059 Boehringer Ingelheim Investigational Site, Witten, Not set

1199.15.49037 Boehringer Ingelheim Investigational Site, Wolfsburg, Not set

1199.15.49060 Boehringer Ingelheim Investigational Site, Worms, Not set

1199.15.30001 Boehringer Ingelheim Investigational Site, Athens, Not set

1199.15.30003 Boehringer Ingelheim Investigational Site, Heraklio, Not set

1199.15.30002 Boehringer Ingelheim Investigational Site, Nea Kifisia, Not set

1199.15.30005 Boehringer Ingelheim Investigational Site, Patras, Not set

1199.15.30004 Boehringer Ingelheim Investigational Site, Thessaloniki, Not set

1199.15.39027 Boehringer Ingelheim Investigational Site, Asti, Not set

1199.15.39002 Boehringer Ingelheim Investigational Site, Avellino, Not set

1199.15.39003 Boehringer Ingelheim Investigational Site, Aviano (pn), Not set

1199.15.39004 Boehringer Ingelheim Investigational Site, Bari, Not set

1199.15.39005 Boehringer Ingelheim Investigational Site, Benevento, Not set

1199.15.39029 Boehringer Ingelheim Investigational Site, Brescia, Not set

1199.15.39040 Boehringer Ingelheim Investigational Site, Catania, Not set

1199.15.39007 Boehringer Ingelheim Investigational Site, Catanzaro, Not set

1199.15.39008 Boehringer Ingelheim Investigational Site, Faenza (RA), Not set

1199.15.39039 Boehringer Ingelheim Investigational Site, Ferrara, Not set

1199.15.39017 Boehringer Ingelheim Investigational Site, Genova, Not set

1199.15.39037 Boehringer Ingelheim Investigational Site, Lecce, Not set

1199.15.39009 Boehringer Ingelheim Investigational Site, Mantova, Not set

1199.15.39033 Boehringer Ingelheim Investigational Site, Meldola (fc), Not set

1199.15.39021 Boehringer Ingelheim Investigational Site, Milano, Not set

1199.15.39028 Boehringer Ingelheim Investigational Site, Milano, Not set

1199.15.39036 Boehringer Ingelheim Investigational Site, Milano, Not set

1199.15.39010 Boehringer Ingelheim Investigational Site, Modena, Not set

1199.15.39026 Boehringer Ingelheim Investigational Site, Monza, Not set

1199.15.39001 Boehringer Ingelheim Investigational Site, Napoli, Not set

1199.15.39022 Boehringer Ingelheim Investigational Site, Padova, Not set

1199.15.39011 Boehringer Ingelheim Investigational Site, Palermo, Not set

1199.15.39031 Boehringer Ingelheim Investigational Site, Palermo, Not set

1199.15.39023 Boehringer Ingelheim Investigational Site, Pisa, Not set

1199.15.39012 Boehringer Ingelheim Investigational Site, Pordenone, Not set

1199.15.39024 Boehringer Ingelheim Investigational Site, Reggio Emilia, Not set

1199.15.39013 Boehringer Ingelheim Investigational Site, Roma, Not set

1199.15.39014 Boehringer Ingelheim Investigational Site, Roma, Not set

1199.15.39034 Boehringer Ingelheim Investigational Site, Rozzano (MI), Not set

1199.15.39030 Boehringer Ingelheim Investigational Site, San Fermo Della Battaglia, Not set

1199.15.39018 Boehringer Ingelheim Investigational Site, Sondrio, Not set

1199.15.39006 Boehringer Ingelheim Investigational Site, Tappino (CB), Not set

1199.15.39019 Boehringer Ingelheim Investigational Site, Torino, Not set

1199.15.39020 Boehringer Ingelheim Investigational Site, Torino, Not set

1199.15.39032 Boehringer Ingelheim Investigational Site, Varese, Not set

1199.15.31009 Boehringer Ingelheim Investigational Site, 's-HERTOGENBOSCH, Not set

1199.15.31005 Boehringer Ingelheim Investigational Site, Amersfoort, Not set

1199.15.31004 Boehringer Ingelheim Investigational Site, Niewegein, Not set

1199.15.31003 Boehringer Ingelheim Investigational Site, Nijmegen, Not set

1199.15.31006 Boehringer Ingelheim Investigational Site, Rotterdam, Not set

1199.15.31002 Boehringer Ingelheim Investigational Site, Utrecht, Not set

1199.15.47003 Boehringer Ingelheim Investigational Site, Bergen, Not set

1199.15.47001 Boehringer Ingelheim Investigational Site, Oslo, Not set

1199.15.47002 Boehringer Ingelheim Investigational Site, Stavanger, Not set

1199.15.47004 Boehringer Ingelheim Investigational Site, Trondheim, Not set

1199.15.48003 Boehringer Ingelheim Investigational Site, Gdansk, Not set

1199.15.48006 Boehringer Ingelheim Investigational Site, Lublin, Not set

1199.15.48001 Boehringer Ingelheim Investigational Site, Warszawa, Not set

1199.15.35102 Boehringer Ingelheim Investigational Site, Coimbra, Not set

1199.15.35104 Boehringer Ingelheim Investigational Site, Coimbra, Not set

1199.15.35101 Instituto Portugues de Oncologia Lisboa Francisco Gentil, Lisboa, Not set

1199.15.35106 Boehringer Ingelheim Investigational Site, Lisboa, Not set

1199.15.35108 Boehringer Ingelheim Investigational Site, Lisboa, Not set

1199.15.35105 Boehringer Ingelheim Investigational Site, Porto, Not set

1199.15.35109 Boehringer Ingelheim Investigational Site, Vila Real, Not set

1199.15.70006 Boehringer Ingelheim Investigational Site, Barnaul, Not set

1199.15.70005 Boehringer Ingelheim Investigational Site, Ekaterinburg, Not set

1199.15.70007 Boehringer Ingelheim Investigational Site, Kazan, Not set

1199.15.70001 Boehringer Ingelheim Investigational Site, Moscow, Not set

1199.15.70002 Boehringer Ingelheim Investigational Site, St. Petersburg, Not set

1199.15.42101 Boehringer Ingelheim Investigational Site, Bratislava, Not set

1199.15.42105 Boehringer Ingelheim Investigational Site, Bratislava, Not set

1199.15.42106 Boehringer Ingelheim Investigational Site, Kosice, Not set

1199.15.42103 Boehringer Ingelheim Investigational Site, Nitra, Not set

1199.15.42104 Boehringer Ingelheim Investigational Site, Poprad, Not set

1199.15.42102 Boehringer Ingelheim Investigational Site, Zilina, Not set

1199.15.34001 Boehringer Ingelheim Investigational Site, Badalona, Not set

1199.15.34003 Boehringer Ingelheim Investigational Site, Barcelona, Not set

1199.15.34006 Boehringer Ingelheim Investigational Site, Girona, Not set

1199.15.34004 Boehringer Ingelheim Investigational Site, Lleida, Not set

1199.15.34002 Boehringer Ingelheim Investigational Site, Madrid, Not set

1199.15.34010 Boehringer Ingelheim Investigational Site, Madrid, Not set

1199.15.34005 Boehringer Ingelheim Investigational Site, Palma de Mallorca, Not set

1199.15.34009 Boehringer Ingelheim Investigational Site, Valencia, Not set

1199.15.46005 Boehringer Ingelheim Investigational Site, Linköping, Not set

1199.15.46001 Boehringer Ingelheim Investigational Site, Lund, Not set

1199.15.46002 Boehringer Ingelheim Investigational Site, Stockholm, Not set

1199.15.46004 Boehringer Ingelheim Investigational Site, Umeå, Not set

1199.15.46003 Boehringer Ingelheim Investigational Site, Uppsala, Not set

1199.15.38006 Boehringer Ingelheim Investigational Site, Cherkasy, Not set

1199.15.38005 Boehringer Ingelheim Investigational Site, Dnepropetrovsk, Not set

1199.15.38004 Boehringer Ingelheim Investigational Site, Donetsk, Not set

1199.15.38002 Boehringer Ingelheim Investigational Site, Kharkiv, Not set

1199.15.38003 Boehringer Ingelheim Investigational Site, Lviv, Not set

1199.15.44006 Boehringer Ingelheim Investigational Site, Derby, Not set

1199.15.44007 Boehringer Ingelheim Investigational Site, Dundee, Not set

1199.15.44003 Boehringer Ingelheim Investigational Site, Glasgow, Not set

1199.15.44001 Boehringer Ingelheim Investigational Site, Guildford, Not set

1199.15.44005 Boehringer Ingelheim Investigational Site, London, Not set

1199.15.44004 Boehringer Ingelheim Investigational Site, Nottingham, Not set

1199.15.44002 Boehringer Ingelheim Investigational Site, Poole, Not set

1199.15.44008 Boehringer Ingelheim Investigational Site, Truro, Not set

Conditions: Ovarian Neoplasms, Peritoneal Neoplasms

Learn More ›

Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

NCT00111787

Completed

This Study was designed to determine how effective and safe a new investigational drug, lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed inflammatory breast cancer. Tumor tissue collected pre-treatment, following 14 days of treatment and at the time of surgical resection will be examined for pathologic response and biologic activity by IHC (immunohistochemistry) within the tumor. Treatment will consist of 14 days of lapatinib monotherapy followed by 12 weeks... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2017

Locations: GSK Investigational Site, Miami, Florida +24 locations

Conditions: Neoplasms, Breast

Learn More ›

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

NCT01493843

Completed

This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/21/2017

Locations: Alabama Oncology, Birmingham, Alabama +119 locations

Alabama Oncology, Birmingham, Alabama

Highlands Oncology Group, Rogers, Arkansas

cCare, Encinitas, California

Kaiser Permanente - Oakland, Oakland, California

Desert Hematology Oncology Group, Rancho Mirage, California

Kaiser Permanente - Roseville, Roseville, California

Kaiser Permanente Sacramento Medical Center, Sacramento, California

Southern CA Permanente Med Grp, San Diego, California

Kaiser Permanente, San Francisco, California

K. Permanente - Santa Clara, Santa Clara, California

Stockton Hema Onc Med Grp Inc, Stockton, California

Kaiser Permanente - Vallejo, Vallejo, California

K. Permanente - Walnut Creek, Walnut Creek, California

Hematology Oncology PC; Bennett Cancer Center, Stamford, Connecticut

Lynn Regional Cancer Center West, Boca Raton, Florida

Florida Cancer Specialists - Fort Myers (Colonial Center Dr), Fort Myers, Florida

Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida

Advanced Medical Specialties, Miami, Florida

Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida

University Cancer & Blood Center, LLC, Athens, Georgia

Peachtree Hematology & Oncology Consultants, Pc, Atlanta, Georgia

Georgia Cancer Specialists, Atlanta, Georgia

Hematology-Oncology of Indiana, Pc, Indianapolis, Indiana

Franklin Square Hospital, Baltimore, Maryland

Massachusetts General Hospital., Boston, Massachusetts

Dana Farber Cancer Inst., Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Wayne State University; Hemat/Onc, 4HW CRC, Detroit, Michigan

Nebraska Methodist Hospital, Omaha, Nebraska

Va Sierra Nevada Health Care System, Reno, Nevada

San Juan Oncology Associates, Farmington, New Mexico

Roswell Park Cancer Inst., Buffalo, New York

Piedmont Hematology Oncology Associates, Winston-Salem, North Carolina

Gabrail Cancer Center, Canton, Ohio

The Christ Hospital, Cincinnati, Ohio

Univ Hosp Case Medical Center, Cleveland, Ohio

Center for Biomedical Research LLC, Knoxville, Tennessee

The Sarah Cannon Research Inst, Nashville, Tennessee

Vanderbilt, Nashville, Tennessee

University of Texas M.D. Anderson Cancer Center, Houston, Texas

Wellmonth Physician Services, Bristol, Virginia

Blue Ridge Cancer Care - Roanoke, Roanoke, Virginia

VA Puget Sound Health Care Sys, Seattle, Washington

Northwest Medical Specialties, Tacoma, Washington

Clinica Universitaria Reina Fabiola, Cordoba, Not set

Instituto FIDES, La Plata, Not set

Isis Centro Especializado de Luces; Oncology, Santa Fe, Not set

Royal Prince Alfred Hospital; Sydney Cancer Centre, Camperdown, New South Wales

St Vincent'S Hospital, Darlinghurst, New South Wales

Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales

Flinders Medical Centre; Medical Oncology, Bedford Park, South Australia

Royal Hobart Hospital; Medical Oncology, Hobart, Tasmania

Footscray Hospital, Footscray, Victoria

Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria

Centro de Oncologia da Bahia - CENOB, Salvador, BA

Clinica de Tratamento e Pesquisa Oncologica - Oncotek, Brasilia, DF

Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ

Liga Norte Riograndense Contra O Câncer, Natal, RN

Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS

Hospital Mae de Deus, Porto Alegre, RS

Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC

Hospital Amaral Carvalho, Jau, SP

Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP

Instituto de Oncologia de Sorocaba - CEPOS, Sorocaba, SP

Mcgill University - Royal Victoria Hospital; Oncology, Montreal, Quebec

Hopital du Sacre-Coeur, Montreal, Quebec

Clinica Santa Maria, Santiago, Not set

Fundacion Arturo Lopez Perez, Santiago, Not set

Instituto Oncologico del sur, Temuco, Not set

Hospital Clinico Vina del Mar, Viña del Mar, Not set

Hopital Morvan, Brest, Not set

Clinique Victor Hugo; Radiotherapie, Le Mans, Not set

Clinique Catherine de Sienne; Service de cancérologie, Nantes, Not set

Ico Rene Gauducheau; Oncologie, Saint Herblain, Not set

Centre Hospitalier de Villefranche sur Saone, Villefranche-sur-Saone, Not set

Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, Not set

Zentralklinik Bad Berka GmbH; Abteilung Onkologie und Hämatologie, Bad Berka, Not set

Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Not set

Krankenhaus Grosshansdorf;Pneumologie & Thoraxchirurgie, Grosshansdorf, Not set

St. Vincentius Kliniken Karlsruhe; Abteilung Hämatologie / Onkologie, Karlsruhe, Not set

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Medizinische Klinik, Pneumologie, Mainz, Not set

Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, Regensburg, Not set

Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Not set

Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie, Villingen-Schwenningen, Not set

Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Not set

Koch Robert Korhaz, Edeleny, Not set

Veszprem Megyei Onkormanyzat Tudogyogyintezet, Farkasgyepu, Not set

Vas Megyei Markusovszky Korhaz ; Pulmonology, Szombathely, Not set

Tudogyogyintezet Torokbalint, Torokbalint, Not set

Zala Megyei Korhaz; Dept of Pulmonary Medicine, Zalaegerszeg, Not set

Shaare Zedek Medical Center; Oncology Dept, Jerusalem, Not set

Meir Medical Center; Oncology, Kfar-Saba, Not set

Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Not set

Ausl Di Bologna-Ospedale Bellaria;U.O. Oncologia Medica, Bologna, Emilia-Romagna

Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia

ASST DI MONZA; Oncologia Medica, Monza, Lombardia

Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico, Orbassano, Piemonte

A.O.U.I. VERONA-OSPEDALE POLICLINICO G.B. ROSSI BORGO ROMA;ONCOLOGIA MEDICA-d.U., Verona, Veneto

Amphia Ziekenhuis, Breda, Not set

Catharina-ziekenhuis; Longgeneeskunde en Tuberculose, Eindhoven, Not set

Universitair Medisch Centrum Groningen, Groningen, Not set

Regional Oncology Center, Chelyabinsk, Not set

Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Not set

City Oncology Hospital; Chemotherapy Dept, Nizhny Novgorod, Not set

Leningrad Regional Clinical Hospital, St Petersburg, Not set

Rsrch Onc Inst of Rosmed Tech; n.a. prof. N.N. Petrov; Dept of Surgery, St. Petersburg, Not set

Hospital Nuestra Señora de Sonsoles; servicio de Oncologia, Avila, Not set

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Not set

Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, Not set

Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Not set

Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Not set

Kiev City Clinical Oncology Center, Kiev, Not set

Volyn Regional Oncology Dispensary, Lutsk, Not set

State Oncology Regional Treatment-Diagnostic Center; Chemotherapy Department, Lviv, Not set

Crimean Republican Institute; Oncology Clin Dispensary; Chemotherapy Dept, Simferopol, Not set

Sumy Reg. Clin. Oncological Dispensary; Thoracall Department, Sumy, Not set

Zaporizhzhia Regional Clinical Oncology Dispensary; Zaporizhzhya State Medical University, Zaporizhzhya, Not set

Royal Surrey County Hospital; St. Lukes Cancer Centre, Guildford, Not set

Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, Not set

Christie Hospital Nhs Trust; Medical Oncology, Manchester, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

NCT01493505

Terminated

The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/22/2017

Locations: Research Site, Birmingham, Alabama +309 locations

Research Site, Birmingham, Alabama

Research Site, Mobile, Alabama

Research Site, Anchorage, Alaska

Research Site, Gilbert, Arizona

Research Site, Peoria, Arizona

Research Site, Phoenix, Arizona

Research Site, Tucson, Arizona

Research Site, Berkeley, California

Research Site, Burbank, California

Research Site, Concord, California

Research Site, Corona, California

Research Site, La Jolla, California

Research Site, Long Beach, California

Research Site, Los Angeles, California

Research Site, Orange, California

Research Site, Oxnard, California

Research Site, Rancho Mirage, California

Research Site, Sacramento, California

Research Site, San Diego, California

Research Site, Aurora, Colorado

Research Site, Englewood, Colorado

Research Site, Bridgeport, Connecticut

Research Site, Farmington, Connecticut

Research Site, Hartford, Connecticut

Research Site, New Britain, Connecticut

Research Site, Stamford, Connecticut

Research Site, Clearwater, Florida

Research Site, Hollywood, Florida

Research Site, Miami, Florida

Research Site, Orlando, Florida

Research Site, St Petersburg, Florida

Research Site, Tampa, Florida

Research Site, Augusta, Georgia

Research Site, Gainesville, Georgia

Research Site, Macon, Georgia

Research Site, Savannah, Georgia

Research Site, Honolulu, Hawaii

Research Site, Chicago, Illinois

Research Site, Decatur, Illinois

Research Site, Evanston, Illinois

Research Site, Hinsdale, Illinois

Research Site, Joliet, Illinois

Research Site, Maywood, Illinois

Research Site, Oak Lawn, Illinois

Research Site, Park Ridge, Illinois

Research Site, Urbana, Illinois

Research Site, Indianapolis, Indiana

Research Site, Munster, Indiana

Research Site, South Bend, Indiana

Research Site, Ames, Iowa

Research Site, Iowa City, Iowa

Research Site, Kansas City, Kansas

Research Site, Edgewood, Kentucky

Research Site, Lexington, Kentucky

Research Site, Covington, Louisiana

Research Site, Lafayette, Louisiana

Research Site, Scarborough, Maine

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Burlington, Massachusetts

Research Site, Danvers, Massachusetts

Research Site, Worcester, Massachusetts

Research Site, Detroit, Michigan

Research Site, Kalamazoo, Michigan

Research Site, Minneapolis, Minnesota

Research Site, Rochester, Minnesota

Research Site, St. Louis Park, Minnesota

Research Site, Jackson, Mississippi

Research Site, Kansas City, Missouri

Research Site, St Louis, Missouri

Research Site, Billings, Montana

Research Site, Lincoln, Nebraska

Research Site, Las Vegas, Nevada

Research Site, Reno, Nevada

Research Site, Lebanon, New Hampshire

Research Site, Hackensack, New Jersey

Research Site, Neptune, New Jersey

Research Site, Voorhees, New Jersey

Research Site, Albuquerque, New Mexico

Research Site, Albany, New York

Research Site, Brightwaters, New York

Research Site, Bronx, New York

Research Site, Buffalo, New York

Research Site, Jamaica, New York

Research Site, Lake Success, New York

Research Site, New York, New York

Research Site, Syracuse, New York

Research Site, Asheville, North Carolina

Research Site, Burlington, North Carolina

Research Site, Chapel Hill, North Carolina

Research Site, Charlotte, North Carolina

Research Site, Concord, North Carolina

Research Site, Durham, North Carolina

Research Site, Wilmington, North Carolina

Research Site, Winston Salem, North Carolina

Research Site, Fargo, North Dakota

Research Site, Akron, Ohio

Research Site, Canton, Ohio

Research Site, Cincinnati, Ohio

Research Site, Cleveland, Ohio

Research Site, Columbus, Ohio

Research Site, Kettering, Ohio

Research Site, Mayfield Heights, Ohio

Research Site, Toledo, Ohio

Research Site, Oklahoma City, Oklahoma

Research Site, Tulsa, Oklahoma

Research Site, Bend, Oregon

Research Site, Abington, Pennsylvania

Research Site, Bethlehem, Pennsylvania

Research Site, Philadelphia, Pennsylvania

Research Site, Pittsburgh, Pennsylvania

Research Site, Radnor, Pennsylvania

Research Site, West Reading, Pennsylvania

Research Site, Providence, Rhode Island

Research Site, Charleston, South Carolina

Research Site, Columbia, South Carolina

Research Site, Greenville, South Carolina

Research Site, Sioux Falls, South Dakota

Research Site, Chattanooga, Tennessee

Research Site, Austin, Texas

Research Site, Bedford, Texas

Research Site, Dallas, Texas

Research Site, Galveston, Texas

Research Site, Houston, Texas

Research Site, San Antonio, Texas

Research Site, The Woodlands, Texas

Research Site, Ogden, Utah

Research Site, Burlington, Vermont

Research Site, Annandale, Virginia

Research Site, Charlottesville, Virginia

Research Site, Norfolk, Virginia

Research Site, Roanoke, Virginia

Research Site, Winchester, Virginia

Research Site, Woodbridge, Virginia

Research Site, Seattle, Washington

Research Site, Tacoma, Washington

Research Site, Wenatchee, Washington

Research Site, Green Bay, Wisconsin

Research Site, Marshfield, Wisconsin

Research Site, Milwaukee, Wisconsin

Research Site, Oshkosh, Wisconsin

Research Site, Sheboygan, Wisconsin

Research Site, Waukesha, Wisconsin

Research Site, Wausau, Wisconsin

Research Site, West Allis, Wisconsin

Research Site, Graz, Not set

Research Site, Innsbruck, Not set

Research Site, Linz, Not set

Research Site, Salzburg, Not set

Research Site, Wien, Not set

Research Site, Bonheiden, Not set

Research Site, Brasschaat, Not set

Research Site, Bruxelles, Not set

Research Site, Charleroi, Not set

Research Site, Duffel, Not set

Research Site, Edegem, Not set

Research Site, Gent, Not set

Research Site, Hasselt, Not set

Research Site, Kortrijk, Not set

Research Site, Leuven, Not set

Research Site, Libramont, Not set

Research Site, Liège, Not set

Research Site, Namur, Not set

Research Site, Oostende, Not set

Research Site, Sint-Niklaas, Not set

Research Site, Turnhout, Not set

Research Site, Wilrijk, Not set

Research Site, Yvoir, Not set

Research Site, Calgary, Alberta

Research Site, Edmonton, Alberta

Research Site, Halifax, Nova Scotia

Research Site, Kingston, Ontario

Research Site, London, Ontario

Research Site, Sault Ste. Marie, Ontario

Research Site, Toronto, Ontario

Research Site, Montreal, Quebec

Research Site, Quebec, Not set

Research Site, Herlev, Not set

Research Site, København Ø, Not set

Research Site, Roskilde, Not set

Research Site, Berlin, Not set

Research Site, Dresden, Not set

Research Site, Düsseldorf, Not set

Research Site, Erlangen, Not set

Research Site, Essen, Not set

Research Site, Frankfurt am Main, Not set

Research Site, Freiburg, Not set

Research Site, Hamburg, Not set

Research Site, Hannover, Not set

Research Site, Kiel, Not set

Research Site, Konstanz, Not set

Research Site, Leipzig, Not set

Research Site, Ludwigsburg, Not set

Research Site, München, Not set

Research Site, Oldenburg, Not set

Research Site, Ravensburg, Not set

Research Site, Rostock, Not set

Research Site, Stuttgart, Not set

Research Site, Tübingen, Not set

Research Site, Ulm, Not set

Research Site, Athens, Not set

Research Site, Larissa, Not set

Research Site, Patra, Not set

Research Site, Thessaloniki, Not set

Research Site, Hong Kong, Not set

Research Site, Kowloon, Not set

Research Site, New Territories, Not set

Research Site, Avellino, Not set

Research Site, Aviano PN, Not set

Research Site, Bari, Not set

Research Site, Bologna, Not set

Research Site, Brescia, Not set

Research Site, Genova, Not set

Research Site, Milano, Not set

Research Site, Napoli, Not set

Research Site, Novara, Not set

Research Site, Palermo, Not set

Research Site, Pisa, Not set

Research Site, Roma, Not set

Research Site, Torino, Not set

Research Site, Nagoya-city, Aichi

Research Site, Kashiwa, Chiba

Research Site, Fukuoka-shi, Fukuoka

Research Site, Kurume-city, Fukuoka

Research Site, Kure-city, Hiroshima

Research Site, Sapporo-city, Hokkaido

Research Site, Morioka-city, Iwate

Research Site, Kitaadachi-gun, Saitama

Research Site, Suntou-gun, Shizuoka

Research Site, Yonago-city, Tottori

Research Site, Tokyo, Not set

Research Site, Goyang-si, Gyeonggi-do, Not set

Research Site, Seoul, Not set

Research Site, Deventer, Not set

Research Site, Leiden, Not set

Research Site, Nijmegen, Not set

Research Site, Rotterdam, Not set

Research Site, Chelyabinsk, Not set

Research Site, Ivanovo, Not set

Research Site, Krasnodar, Not set

Research Site, Moscow, Not set

Research Site, Obninsk, Not set

Research Site, Pyatigorsk, Not set

Research Site, Saint Petersburg, Not set

Research Site, Ufa, Not set

Research Site, Voronezh, Not set

Research Site, Zaragoza, Aragón

Research Site, Oviedo, Asturias

Research Site, Palma de Mallorca, Baleares

Research Site, Badalona, Cataluña

Research Site, Barcelona, Cataluña

Research Site, Girona, Cataluña

Research Site, Lleida, Cataluña

Research Site, Valencia, Comunidad Valenciana

Research Site, El Palmar, Murcia

Research Site, Madrid, Not set

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

Learn More ›

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

NCT00738699

Terminated

The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer

Gender:

FEMALE

Ages:

Between 18 years and 99 years

Trial Updated:

02/10/2017

Locations: Southern Cancer Center, Mobile, Alabama +60 locations

Southern Cancer Center, Mobile, Alabama

St. Joseph's Hospital and Medical Center, Phoenix, Arizona

California Cancer Care, Inc., Greenbrae, California

Moores UC San Diego Cancer Center, La Jolla, California

USC/Norris Comprehensive Cancer Center, Los Angeles, California

Monterey Bay Oncology, Monterey, California

Jupiter Medical Center, Jupiter, Florida

Innovative Medical Research of South Florida, Inc., Miami, Florida

Florida Hospital Cancer Institute, Orlando, Florida

Sarasota Memorial Hospital, Sarasota, Florida

Memorial Health University Medical Center, Savannah, Georgia

Central DuPage Hospital, Winfield, Illinois

St. Vincent Gynecologic Oncology, Indianapolis, Indiana

Hematology and Oncology Specialists, LLC, Metairie, Louisiana

Johns Hopkins Hospital, Baltimore, Maryland

Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland

Henry Ford Health System, Detroit, Michigan

Morristown Memorial Hospital, Morristown, New Jersey

Schwartz Gynecologic Oncology, PLLC, Brightwaters, New York

Arena Oncology Associates, PC, Lake Success, New York

St. Luke's Roosevelt Hospital Center, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Piedmont Hematology Oncology Associates, PA, Winston Salem, North Carolina

Cleveland Clinic, Cleveland, Ohio

Signal Point Clinical Research Center, Middletown, Ohio

Cancer Care Associates, Tulsa, Oklahoma

Abington Memorial Hospital, Abington, Pennsylvania

Magee-Women's Hospital of UPMC, Pittsburgh, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

International Beneficence Clinical Research, LLC, Harlingen, Texas

South Texas Oncology & Hematology PA, San Antonio, Texas

Scott & White Memorial Hospital and Clinic, Temple, Texas

Utah Cancer Specialists, Salt Lake City, Utah

Northern Virginia Pelvic Surgery Associates, Annandale, Virginia

Prince of Wales Hospital, Randwick, New South Wales

Westmead Hospital, Westmead, New South Wales

Royal Brisbane & Women's Hospital, Herston, Queensland

The Burnside War Memorial Hospital, Inc., Toorak Gardens, South Australia

Monash Medical Centre, East Bentleigh, Victoria

Mercy Hospital for Women, Heidelburg, Victoria

The Royal Women's Hospital, Parkville, Victoria

Sir Charles Gairdner Hospital, Nedlands, Western Australia

St. John of God Hospital, Subiaco, Western Australia

AZ Greninge Hospital, Kortrijk, Not set

University Hospitals Leuven, Leuven, Not set

CHU de Liege, Liege, Not set

Tom Baker Cancer Centre, Calgary, Alberta

BC Cancer Agency, Kelowna, British Columbia

Juravinski Cancer Centre, Hamilton, Ontario

Sunnybrook Health Sciences Centre, Toronto, Ontario

UMCG, Groningen, Not set

University Hospital Maastricht, Maastricht, Not set

UMC Utrecht, Utrecht, Not set

Hospital Universitario Son Dureta, Palma de Mallorca, Baleares

Hospital de Son Llatzer, Palma de Mallorca, Baleares

Hospital de Mataro, Mataro, Barcelona

Corporacio Sanitaria Parc Taulis, Sabadell, Barcelona

Consorci Sanitari de Terrassa, Terrassa, Barcelona

Fundacion Hospital Alcorcon, Alcorcon, Madrid

Hospital Clinic I Provincial, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Conditions: Ovarian Cancer

Learn More ›

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT00883116

Terminated

The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

01/27/2017

Locations: University Of South Alabama, Mobile, Alabama +92 locations

University Of South Alabama, Mobile, Alabama

Rocky Mountain Gynecologic Oncology, Englewood, Colorado

Peter E. Schwartz, Md, New Haven, Connecticut

Hematology Oncology, P.C., Stamford, Connecticut

Gynecologic Oncology Assoc.,Inc, Hollywood, Florida

Florida Hospital Cancer Institute, Orlando, Florida

Sarasota Memorial Health Care System, Sarasota, Florida

H. Lee Moffitt Cancer Center, Tampa, Florida

Georgia Health Science University, Augusta, Georgia

Sudarshan K. Sharma, Md, Hinsdale, Illinois

Central Dupage Hospital Cancer Center, Warrenville, Illinois

St. Vincent Hospital And Health Care Center, Inc., Indianapolis, Indiana

Hematology And Oncology Specialists, Llc, Marrero, Louisiana

Women'S Health Specialists, Rockville, Maryland

Sparrow Regional Cancer Center, Lansing, Michigan

University Of Minnesota, Minneapolis, Minnesota

Saint Dominic's Gynecologic Oncology, Jackson, Mississippi

Matthew A Powell, Md, Saint Louis, Missouri

Blumenthal Cancer Center, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Peggy And Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma

Tulsa Cancer Institute, Tulsa, Oklahoma

Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania

Magee-Womens Hospital Of Upmc Laboratory, Pittsburgh, Pennsylvania

Women & Infants Hospital Of Ri, Providence, Rhode Island

Cancer Centers Of The Carolinas, Greenville, South Carolina

Tennessee Gynecologic Oncology Group, Llc, Chattanooga, Tennessee

University Of Virginia, Charlottesville, Virginia

Local Institution, Rosario, Santa Fe

Local Institution, La Rioja, Not set

Local Institution, Salta, Not set

Local Institution, Milton, Queensland

Local Institution, East Bentleigh, Victoria

Local Institution, Gent, Not set

Local Institution, Leuven, Not set

Local Institution, Porto Alegre, Rio Grande Do Sul

Local Institution, Barretos, Sao Paulo

Local Institution, Jau, Sao Paulo

Local Institution, Sao Paulo, Not set

Local Institution, Calgary, Alberta

Local Institution, Surrey, British Columbia

Local Institution, Vancouver, British Columbia

Local Institution, Halifax, Nova Scotia

Local Institution, Toronto, Ontario

Local Institution, Fleurimont, Quebec

Local Institution, Montreal, Quebec

Local Institution, Brno, Not set

Local Institution, Hradec Kralove, Not set

Local Institution, Copenhagen, Not set

Local Institution, Herlev, Not set

Local Institution, Odense C, Not set

Local Institution, Paris, Not set

Local Institution, Poitiers, Not set

Local Institution, Saint Herblain Cedex, Not set

Local Institution, Villejuif Cedex, Not set

Local Institution, Athens, Not set

Local Institution, Budapest, Not set

Local Institution, Miskolc, Not set

Local Institution, Brescia, Not set

Local Institution, Campobasso, Not set

Local Institution, Meldola (fc), Not set

Local Institution, Milano, Not set

Local Institution, Monza, Not set

Local Institution, Roma, Not set

Local Institution, Df, Distrito Federal

Local Institution, Mexico City, Distrito Federal

Local Institution, Mexico, Distrito Federal

Local Institution, Monterrey, Distrito Federal

Local Institution, Tlalpan, Distrito Federal

Local Institution, Guadalajara, Jalisco

Local Institution, Bergen, Not set

Local Institution, Oslo, Not set

Local Institution, Lima, Not set

Local Institution, Ivanovo, Not set

Local Institution, Moscow, Not set

Local Institution, Obninsk, Not set

Local Institution, St Pertersburg, Not set

Local Institution, St Petersburg, Not set

Local Institution, Barcelona, Not set

Local Institution, Madrid, Not set

Local Institution, Valencia, Not set

Local Institution, Goteborg, Not set

Local Institution, Linkoping, Not set

Local Institution, Stockholm, Not set

Local Institution, Umea, Not set

Local Institution, Uppsala, Not set

Local Institution, Bristol, Avon

Local Institution, Glasgow, Dumfries & Galloway

Local Institution, Nottingham, Nottinghamshire

Local Institution, Leeds, Yorkshire

Conditions: Endometrial Cancer

Learn More ›

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

NCT01572727

Completed

This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

01/27/2017

Locations: Ironwood Cancer and Research Centers SC, Chandler, Arizona +112 locations

Ironwood Cancer and Research Centers SC, Chandler, Arizona

Arizona Oncology Associates Dept of Oncology, Phoenix, Arizona

Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas

California Cancer Care Marian Speciality, Greenbrae, California

Rocky Mountain Cancer Centers RMCC Hale Pkwy, Greenwood Village, Colorado

H. Lee Moffitt Cancer Center & Research Institute SC, Tampa, Florida

Emory University School of Medicine/Winship Cancer Institute Dept.of WinshipCancerInst. (2), Atlanta, Georgia

Northwest Georgia Oncology Center NW Georgia Onc, Marietta, Georgia

University of Kansas Cancer Center Univ Kansas 2, Kansas City, Kansas

Norton Healthcare, Inc., Louisville, Kentucky

Washington University School of Medicine Regulatory, St. Louis, Missouri

University of Nebraska Medical Center Unv Nebraska Med Ctr (2), Omaha, Nebraska

University of New Mexico Cancer Research Center Dept of Univ New Mexico, Albuquerque, New Mexico

New York Oncology Hematology, P.C. Dept. of New York Oncology. PC, Troy, New York

Ohio State Comprehensive Cancer Center/James Cancer Hospital SC-1, Columbus, Ohio

University of Oklahoma Health Sciences Center OUHSC 2, Oklahoma City, Oklahoma

Northwest Cancer Specialists Vancouver Loc, Portland, Oregon

Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas, Texas

University of Texas Southwestern Medical Center Harry Hines, Dallas, Texas

Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio, San Antonio, Texas

Medical Oncology & Hematology Associates of Northern VA Med Onc Hem Northern VA, Reston, Virginia

Novartis Investigative Site, Sydney, New South Wales

Novartis Investigative Site, Geelong, Victoria

Novartis Investigative Site, Parkville, Victoria

Novartis Investigative Site, Nedlands, Western Australia

Novartis Investigative Site, Salzburg, Not set

Novartis Investigative Site, Vienna, Not set

Novartis Investigative Site, Charleroi, Not set

Novartis Investigative Site, Liege, Not set

Novartis Investigative Site, Liège, Not set

Novartis Investigative Site, Ottignies, Not set

Novartis Investigative Site, Sint-Niklaas, Not set

Novartis Investigative Site, Wilrijk, Not set

Novartis Investigative Site, Fortaleza, CE

Novartis Investigative Site, São Paulo, SP

Novartis Investigative Site, Montreal, Quebec

Novartis Investigative Site, Brno, Not set

Novartis Investigative Site, Olomouc, Not set

Novartis Investigative Site, Praha 2, Not set

Novartis Investigative Site, Angers Cedex 02, Not set

Novartis Investigative Site, Bordeaux, Not set

Novartis Investigative Site, Creteil, Not set

Novartis Investigative Site, La Roche sur Yon cedex 9, Not set

Novartis Investigative Site, Le Mans Cedex, Not set

Novartis Investigative Site, Marseille, Not set

Novartis Investigative Site, Nice Cedex 2, Not set

Novartis Investigative Site, Saint Herblain cedex, Not set

Novartis Investigative Site, Toulouse Cedex 9, Not set

Novartis Investigative Site, Villejuif Cedex, Not set

Novartis Investigative Site, Bonn, Not set

Novartis Investigative Site, Dresden, Not set

Novartis Investigative Site, Erlangen, Not set

Novartis Investigative Site, Frankfurt, Not set

Novartis Investigative Site, Fulda, Not set

Novartis Investigative Site, Mainz, Not set

Novartis Investigative Site, Muenchen, Not set

Novartis Investigative Site, Ravensburg, Not set

Novartis Investigative Site, Ulm, Not set

Novartis Investigative Site, Hong Kong SAR, Not set

Novartis Investigative Site, Budapest, Not set

Novartis Investigative Site, Debrecen, Not set

Novartis Investigative Site, Szolnok, Not set

Novartis Investigative Site, Ramat Gan, Not set

Novartis Investigative Site, Tel Aviv, Not set

Novartis Investigative Site, Cona, FE

Novartis Investigative Site, Genova, GE

Novartis Investigative Site, Monza, MB

Novartis Investigative Site, Messina, ME

Novartis Investigative Site, Milano, MI

Novartis Investigative Site, Nagoya-city, Aichi

Novartis Investigative Site, Nagoya, Aichi

Novartis Investigative Site, Sapporo, Hokkaido

Novartis Investigative Site, Isehara-city, Kanagawa

Novartis Investigative Site, Kawasaki-city, Kanagawa

Novartis Investigative Site, Yokohama, Kanagawa

Novartis Investigative Site, Kumamoto City, Kumamoto

Novartis Investigative Site, Suita-city, Osaka

Novartis Investigative Site, Koto, Tokyo

Novartis Investigative Site, Osaka, Not set

Novartis Investigative Site, Seoul, Korea

Novartis Investigative Site, Breda, Not set

Novartis Investigative Site, Rotterdam, Not set

Novartis Investigative Site, St.- Petersburg, Russia

Novartis Investigative Site, St. Petersburg, Not set

Novartis Investigative Site, Singapore, Not set

Novartis Investigative Site, Johannesburg, Not set

Novartis Investigative Site, Cordoba, Andalucia

Novartis Investigative Site, Malaga, Andalucia

Novartis Investigative Site, Sevilla, Andalucia

Novartis Investigative Site, Barcelona, Catalunya

Novartis Investigative Site, Hospitalet de LLobregat, Catalunya

Novartis Investigative Site, Valencia, Comunidad Valenciana

Novartis Investigative Site, A Coruna, Galicia

Novartis Investigative Site, La Laguna, Santa Cruz de Tenerife

Novartis Investigative Site, Madrid, Not set

Novartis Investigative Site, Zaragoza, Not set

Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC

Novartis Investigative Site, New Taipei City, Not set

Novartis Investigative Site, Taipei, Not set

Novartis Investigative Site, Maidstone, Kent

Novartis Investigative Site, Glasgow - Scotland, Not set

Novartis Investigative Site, London, Not set

Novartis Investigative Site, Wirral, Not set

Conditions: Breast Cancer

Learn More ›

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

NCT02204345

Terminated

A multi-center Phase Ib/II study of the combination of RO5479599 with carboplatin and paclitaxel once in every 3 week (q3w) regimen to evaluate the safety and tolerability.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/24/2017

Locations: Not set, Toronto, Ontario +5 locations

Conditions: Squamous Non-Small Cell Lung Cancer

Learn More ›

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

NCT01457846

Terminated

The purpose of this study is to assess the efficacy, safety and tolerability of AZD4547 compared with paclitaxel in patients with advanced gastric or lower-oesophageal cancer whose tumours are found to have FGFR2 polysomy or gene amplification.

Gender:

ALL

Ages:

Between 25 years and 130 years

Trial Updated:

01/16/2017

Locations: Research Site, Brussels (Anderlecht), Not set +60 locations

Research Site, Brussels (Anderlecht), Not set

Research Site, Brussels (Woluwé-St-Lambert), Not set

Research Site, Leuven, Not set

Research Site, Liege, Not set

Research Site, Plovdiv, Not set

Research Site, Sofia, Not set

Research Site, Vratza, Not set

Research Site, Fredericton, New Brunswick

Research Site, Toronto, Ontario

Research Site, Brno, Not set

Research Site, Olomouc, Not set

Research Site, Praha 2, Not set

Research Site, Saint Cloud, Not set

Research Site, Villejuif, Not set

Research Site, Hamburg, Not set

Research Site, Mainz, Not set

Research Site, Budapest, Not set

Research Site, Debrecen, Not set

Research Site, Nyíregyháza, Not set

Research Site, Bangalore, Not set

Research Site, Chennai, Not set

Research Site, Hyderabad, Not set

Research Site, Nagpur, Not set

Research Site, Pune, Not set

Research Site, Vellore, Not set

Research Site, Ancona, Not set

Research Site, Milano, Not set

Research Site, Pisa, Not set

Research Site, Roma, Not set

Research Site, Chiba-shi, Not set

Research Site, Chuo-ku, Not set

Research Site, Koto-ku, Not set

Research Site, Nagoya-shi, Not set

Research Site, Sapporo-shi, Not set

Research Site, Takatsuki-shi, Not set

Research Site, Anyang-si, Not set

Research Site, Daegu, Not set

Research Site, Hwasun-gun, Not set

Research Site, Jeonju-si, Not set

Research Site, Seongnam-si, Not set

Research Site, Seoul, Not set

Research Site, Brasov, Not set

Research Site, Cluj Napoca, Not set

Research Site, A Coruña, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Oviedo, Not set

Research Site, Santander, Not set

Research Site, Sevilla, Not set

Research Site, Keelung, Not set

Research Site, Taichung, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Kharkiv, Not set

Research Site, Lviv, Not set

Research Site, Aberdeen, Not set

Research Site, London, Not set

Research Site, Maidstone, Not set

Research Site, Manchester, Not set

Research Site, Sutton, Not set

Research Site, Wolverhampton, Not set

Conditions: Gastro-oesophageal Junction Cancer, Gastric Cancer

Learn More ›